CAR T Cells to Target GD2 for DMG — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CAR T Cells to Target GD2 for DMG — Stella

Recruiting

Back to Diffuse Midline Glioma, H3 K27M-Mutant trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United Kingdom

Great Ormond Street Hospital, London

Key details

Phase

Early testing

Sponsor

University College, London

Enrollment target

~12 participants

Started

August 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Last updated September 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov